Currently, there are 64.56M common shares owned by the public and among those 62.27M shares have been available to trade.
The company’s stock has a 5-day price change of 0.75% and 61.16% over the past three months. BPMC shares are trading 11.57% year to date (YTD), with the 12-month market performance up to 48.31% higher. It has a 12-month low price of $73.04 and touched a high of $129.49 over the same period. BPMC has an average intraday trading volume of 3.25 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.73%, 11.02%, and 30.90% respectively.
Institutional ownership of Blueprint Medicines Corp (NASDAQ: BPMC) shares accounts for 106.48% of the company’s 64.56M shares outstanding.
It has a market capitalization of $8.37B and a beta (3y monthly) value of 0.94. The earnings-per-share (ttm) stands at -$2.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.20% over the week and 0.21% over the month.
Earnings per share for the fiscal year are expected to increase by 34.48%, and 231.01% over the next financial year.
Looking at the support for the BPMC, a number of firms have released research notes about the stock. Wedbush stated their Neutral rating for the stock in a research note on June 02, 2025, with the firm’s price target at $129. Morgan Stanley coverage for the Blueprint Medicines Corp (BPMC) stock in a research note released on March 20, 2025 offered a Equal-Weight rating with a price target of $100. Wolfe Research was of a view on March 18, 2025 that the stock is Outperform, while Jefferies gave the stock Buy rating on March 17, 2025, issuing a price target of $135. Scotiabank on their part issued Sector Outperform rating on March 07, 2025.
